The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript
The headline numbers for The Cooper Companies (COO) give insight into how the company performed in the quarter ended October 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Cooper Companies (COO) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.04 per share a year ago.
COO is set to post Q4 earnings as MyDAY momentum offsets Clariti and APAC softness, with revenues and earnings expected to rise.
Evaluate the expected performance of The Cooper Companies (COO) for the quarter ended October 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies may strongly outperform the S&P 500 going forward, especially in a recessionary environment, rebounding from 2025's sell-off. COO trades at decade-low enterprise valuations, with renewed insider buying, positive trading momentum, and a history of resilience during economic downturns. The company leads the global contact lens market, maintains a solid balance sheet, and just expanded its share repurchase program by $1 billion.
COO's premium lens strategy, MiSight myopia leadership, and fertility portfolio fuel long-term growth despite near-term headwinds.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either The Cooper Companies (COO) or Merit Medical (MMSI). But which of these two stocks is more attractive to value investors?
The consensus price target hints at a 26.5% upside potential for The Cooper Companies (COO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
COO's Q3 results may top estimates, powered by strong demand for MyDay lenses, Biofinity gains and surgical product resilience despite fertility softness.